Latest News in the pharma Industry

Policy & Regulation

FDA Concerns About Therapeutic Equivalence with Two Generic Versions of Concerta Tablets

FDA Concerns About Therapeutic Equivalence with Two Generic Versions of Concerta Tablets

14 Nov 2014

Read more 
FDA Accepts for Review the NDA for Boehringer Ingelheim's Spiriva Respimat Inhalation Spray for Asthma

FDA Accepts for Review the NDA for Boehringer Ingelheim's Spiriva Respimat Inhalation Spray for Asthma

6 Nov 2014

Read more 
Lilly's Cyramza in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy

Lilly's Cyramza in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy

6 Nov 2014

Read more 
Approval in Baltics for AirFluSal Forspiro

Approval in Baltics for AirFluSal Forspiro

4 Nov 2014

Read more 
EMA Accepts Marketing Authorization Application for Oleogel-S10

EMA Accepts Marketing Authorization Application for Oleogel-S10

3 Nov 2014

Read more 
FDA Approves Baxter's Obizur for Acquired Hemophilia A

FDA Approves Baxter's Obizur for Acquired Hemophilia A

29 Oct 2014

Read more 
Novo Nordisk Receives Subpoena from US Attorney

Novo Nordisk Receives Subpoena from US Attorney

29 Oct 2014

Read more 
NICE Draft Guidance Recommends Rivaroxaban to Prevent Blood Clots in Heart Attack Patients

NICE Draft Guidance Recommends Rivaroxaban to Prevent Blood Clots in Heart Attack Patients

27 Oct 2014

Read more 
FDA Accepts Filing of NDA for Empagliflozin/Metformin Fixed-Dose Combination

FDA Accepts Filing of NDA for Empagliflozin/Metformin Fixed-Dose Combination

22 Oct 2014

Read more 
FDA Advisory Committee Unanimously Recommends Approval of Novartis' AIN457 for Patients with Moderate-to-Severe Plaque Psoriasis

FDA Advisory Committee Unanimously Recommends Approval of Novartis' AIN457 for Patients with Moderate-to-Severe Plaque Psoriasis

21 Oct 2014

Read more 
FDA Approves Boehringer Ingelheim's Ofev as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis

FDA Approves Boehringer Ingelheim's Ofev as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis

16 Oct 2014

Read more 
FDA Approves Gilead’s Harvoni, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

FDA Approves Gilead’s Harvoni, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

14 Oct 2014

Read more